复方樟柳碱治疗中心性浆液性脉络膜视网膜病变的疗效观察

目的:考察复方樟柳碱治疗中心性浆液性脉络膜视网膜病变的疗效和安全性。方法:采用随机对照方法,将101例中心性浆液性脉络膜视网膜病变患者随机分为治疗组(53例)和对照组(48例),治疗组给予复方樟柳碱注射液2mL,均作患眼侧颞浅动脉旁皮下注射,每日1次,对照组给予传统药物口服治疗,疗程均为30d。以患者自诉Amsler表中心暗点及变形情况,最佳矫正视力及平均光敏感度为观察指标。结果:治疗前2组各指标无显著性差异(P>0.05),治疗后1个月治疗组各项指标均比对照组显著好转(P<0.05),治疗后3个月2组视力提高和Amsler表中心暗点及变形情况无显著性差异(P>0.05),治疗组平均光敏感度高于对照组(P<0.01)。治疗组除个别患者有短暂口干、头晕及心慌外,未发现严重不良反应。结论:复方樟柳碱治疗中心性浆液性脉络膜视网膜病变,能保护黄斑的视功能,缩短病程,安全、有效。

Compound Anisodine in the Treatment of Central Serous Chorioretinopathy:Clinical Observation

OBJECTIVE： To investigate the effect and the safety of compound anisodine injection in the treatment of central serous chorioretinopathy （CSC）. METHODS： A random controlled study was performed in which a total, of 101 CSC cases were assigned into 2 groups randomly： 53 （treatment group） were injected subcutaneously compound anisodine injection 2 mL q.d around superficial temporal arteries in the affected eyes for 30 days, and 48 （control group） received traditional oral medication for 30 days. The major outcome measures were the central scotoma （Amsler chart complained by patients themselves） and deformation, the best corrected visual acuity and average light sensitivity. RESULTS： There was no significant difference between the treatment group and the control, group before treatment （P ~〉0.05）, but all the outcome measures at 1 month in the treatment group were significantly improved as compared with control group （P〈0.05） . At 3 months, there were no significant difference between the two groups in central scotoma （Amsler chart） and best corrected visual acuity （P 〉 0.05）. The mean light sensitivity in the treatment group was better than in control, group （P 〈0.01）. No severe adverse effect was noted except mild ones such as temporary dry mouth, dizziness and palpitation in a few cases. CONCLUSION： Compound anisodine is a safe and effective therapy for CSC for it can shorten the course of CSC while protecting the visual function of macula lutea.